

# Predictors of poor outcomes in juvenile dermatomyositis: what do we know? A narrative review

Ana Martins,<sup>1,2</sup> Sara Ganhão,<sup>3</sup> Francisca Aguiar,<sup>3</sup> Mariana Rodrigues,<sup>2,3</sup> Iva Brito<sup>2,3</sup>

<sup>1</sup>Department of Rheumatology, Centro Hospitalar Universitário de São João, Porto; <sup>2</sup>Medicine Department, Faculty of Medicine, University of Porto; <sup>3</sup>Pediatric and Young Adult Rheumatology Unit, Centro Hospitalar Universitário de São João, Porto, Portugal

**Correspondence:** Ana Martins, Department of Rheumatology, Centro Hospitalar Universitário de São João, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal.

E-mail: [anaigmartins.med@gmail.com](mailto:anaigmartins.med@gmail.com)

**Key words:** juvenile dermatomyositis, poor outcomes, mortality, disease severity.

## Summary

**Objective.** Juvenile dermatomyositis (JDM) is a rare chronic systemic inflammatory disorder with a highly variable clinical course. It is important to identify the patients at risk of developing more severe disease. However, based on the existing literature, there is a lack of data regarding predictors of poor outcomes. Obtaining knowledge about clinical and laboratory risk factors for disease progression and severity at an earlier stage of the disease could potentially lead to a better long-term prognosis for patients with JDM.

**Methods.** A narrative review to identify risk factors for poor outcomes in patients with JDM, such as death, severe disease, refractory disease, and functional impairment, was conducted. A total of 27 articles were included.

**Results.** Certain clinical manifestations and immunology features appear to worsen the prognosis in children with JDM. The recognition of these risk factors is essential for all pediatric rheumatologists as it allows the earlier identification of patients with potentially worse outcomes. These patients should receive closer follow-up and aggressive and individualized therapy to reduce their morbimortality.

**Conclusions.** Additional research is needed not only to identify more predictors of worse outcomes but also more effective treatment approaches targeted toward these patients.

## Introduction

Juvenile dermatomyositis (JDM) is a rare chronic systemic inflammatory disorder of childhood, with an incidence of 2-3 per million children per year (1, 2). Prior to the early 1960s, there were no effective treatments for children with JDM, resulting in poor outcomes, with approximately one-third incurring mortality and one-third serious disability (3). However, with the introduction of corticosteroids and other immunosuppressive agents, the mortality rate dropped to less than 2-3%, and a decrease in disease-related morbidity was observed as well (3). Nevertheless, some children have refractory disease and develop irreversible damage and disabilities that markedly impact their quality of life.

Because the clinical course of JDM is highly variable, it is

important to identify the patients at risk of developing a more severe disease. However, based on the existing literature, there is a lack of data regarding predictors of poor outcomes. Obtaining knowledge about clinical and laboratory risk factors for disease progression and severity at an earlier stage of the disease could potentially lead to a better long-term prognosis for patients with JDM. Therefore, to help physicians identify patients at risk of developing severe disease, we aim to review the literature and identify different outcomes (such as mortality, severe disease, refractory disease, and functional impairment) and possible associated risk factors.

## Methods

We searched PubMed using the terms “juvenile dermatomyositis” and “outcomes”, “prognostic factors”, “disease activity”, “mortality” or “functional impairment”, for articles published in English or Portuguese, from January 1, 2000, to December 31, 2022. From a total of 613 articles, 22 relevant articles about the predictors of different outcomes (mortality, severe disease, refractory disease, and functional impairment) were included. In addition, the reference lists of the included studies were manually searched for additional eligible studies, resulting in a total of 27 articles included in this narrative review.

## Results

### Predictors of mortality

A previous study that included 405 patients with juvenile idiopathic inflammatory myopathies (JIIM), comprising 329 with JDM, 30 with juvenile polymyositis, and 46 with juvenile connective tissue disease-associated myositis, aimed to identify risk factors for mortality. The authors found that the presence of antisynthetase antibodies (especially anti-PL-12 antibodies) and, to a lesser extent, the presence of anti-Ku antibodies seems to predict an increased risk of mortality (4). In terms of illness features, illness severity at onset, older age at diagnosis, overlap with other connective tissue diseases, and delay in diagnosis were associated with higher mortality (4). Dysphagia, dysphonia, abdominal perfora-

tion, interstitial lung disease, Raynaud's phenomenon, and weight loss were the clinical features present prior to or at diagnosis that were recognized as mortality risk factors (4). To the best of our knowledge, this is the only study aimed at identifying predictors of mortality in patients with JDM. Table 1 describes the clinical features associated with poor outcomes in JDM patients.

### Predictors of disease severity

Furthermore, certain factors have been identified as potential predictors of disease severity. Insidious onset and chronic course (polycyclic or continuous), along with the presence of calcinosis or lipodystrophy, seem to be related to chronicity and higher disease activity (5, 6). In a retrospective study, Ravelli *et al.* evaluated 490 patients with JDM from inception cohorts seen between 1980 and 2004 in 27 centers in Europe (United Kingdom and Italy) and Latin

America (Argentina, Brazil, and Mexico). They found that chronic course (polycyclic or continuous) appears to predict higher muscle weakness, as indicated by lower values on 8-muscle Manual Muscle Testing (7), and on the Childhood Myositis Assessment Scale (CMAS) (8), as well as higher disease activity on both Myositis Disease Activity Assessment (MYOACT) (9) and Disease Activity Score (DAS) (5, 10). Furthermore, an insidious disease onset predicted continued disease activity on both DAS and MYOACT (5). Additionally, the presence of calcinosis or lipodystrophy was associated with a greater cumulative duration of active disease (5). A retrospective inception cohort of 59 patients diagnosed with JDM corroborated calcinosis as a predictor of higher disease activity based on MYOACT (6). In a cohort of 84 patients with JDM, Stringer *et al.* found that the presence of rash, Gottron papules, and nailfold abnormalities 6 months after the

**Table 1.** Clinical features associated with poor outcomes in juvenile dermatomyositis patients.

Clinical features associated with poor outcomes in JDM	References
<b>Higher mortality</b>	
Illness severity at onset	(4)
Older age at diagnosis	
Overlap with other connective tissue disease	
Delay in diagnosis	
Presence of dysphagia	
Presence of dysphonia	
Presence of abdominal perforation	
Presence of interstitial lung disease	
Presence of Raynaud phenomenon	
Presence of weight loss	
<b>Higher disease severity</b>	
Insidious onset	
Chronic course (polycyclic or continuous)	
Presence of calcinosis	
Presence of lipodystrophy	
Presence of nailfold abnormalities	
Higher disease damage in the first year of diagnosis	
Presence of abnormal subcutaneous fat signal on MRI	(5, 6, 11-15)
<b>Higher risk of extramuscular involvement</b>	
Lung involvement	(24, 26-28)
Presence of reduced nailfold capillary density	
Presence of vasculopathic features in muscle and skin biopsies	
Skin ulceration and gastrointestinal tract involvement	(26-28)
Presence of vasculopathic features in muscle and skin biopsies	
Calcinosis	(5, 28-31)
Latin Americans	
Longer disease duration	
Chronic and active disease	
Delay in diagnosis	
Younger age at onset	
Presence of periungual capillary changes at capillaroscopy	
Presence of vasculopathic features in muscle and skin biopsies	
Lipodystrophy	(5, 32)
Latin Americans	
Longer disease duration	
Chronic and active disease	
<b>Higher functional impairment</b>	
Female gender	(5, 31, 33, 34)
Delay in diagnosis	
Inappropriate treatment	
Chronic disease course	

JDM, juvenile dermatomyositis; MRI, magnetic resonance imaging.

diagnosis was associated with a longer time to remission (11). Moreover, nail fold capillary abnormalities have long been recognized as a predictor of a chronic disease course and can be considered a noninvasive measure of disease activity (12-15). Numerous authors have identified an association between nailfold capillary abnormalities, particularly the loss of end-row nailfold capillaries, and the severity of muscle involvement (assessed by CMAS and muscle DAS) as well as skin involvement severity (evaluated through Skin DAS) (12-15). Additionally, the evidence of disease damage during the first year of diagnosis seems to predict ongoing active disease in long-term follow-up in a cohort of 59 patients with JDM (6). Specific antibodies have also emerged as crucial indicators of disease severity. Notably, the presence of anti-transcription intermediary factor 1 (TIF-1)- $\gamma$ , antisynthetase, anti-nuclear matrix protein 2 (NXP-2), anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), anti-signal recognition particle (SRP), and anti-Ro-52 antibodies has been associated with an increased risk of severe, chronic, and refractory disease (16-20). In addition, patients with anti-melanoma differentiation-associated gene 5 (MDA-5) antibodies appear to require long-term treatment despite the presence of less severe changes in muscle biopsy (21). On the other hand, despite being associated with higher muscle weakness and dysphagia, anti-Mi-2 antibodies seem to confer a better prognosis due to a good response to conventional treatment (17). Table 2 presents the myositis-specific and myositis-associated antibodies and their implications for JDM prognosis.

Magnetic resonance imaging (MRI) findings at presentation seem to exert an influence on the subsequent clinical outcome (22). In a cohort of 45 patients with JDM who underwent a pelvic and thigh MRI, changes in the muscle or fascia were not found to be reliable predictors of clinical outcomes in children. However, the presence of abnormal subcutaneous fat signals appeared to be significantly associated with a more aggressive and chronic disease course (22).

## Predictors of extramuscular involvement

Regarding extramuscular and extracutaneous involvement, specific autoantibodies seem to play a significant role. The presence of anti-MDA-5, anti-synthetase, and anti-Ro-52 antibodies has been associated with an increased risk of interstitial lung disease (ILD) (16, 18, 19, 23). Rider *et al.* found that anti-synthetase antibodies were associated with a higher risk of ILD compared to other antibodies studied (anti-Mi-2, anti-SRP, anti-NXP-2, and anti-TIF-1- $\gamma$ ) (18). A study involving 285 JDM patients, 21 of those positive for anti-MDA-5, showed that these antibodies were associated with ILD (23). Additionally, another study that included 302 patients with JDM, of whom 42 were positive for anti-Ro-52, found that these antibodies were strongly associated with ILD (19).

Furthermore, a reduced nailfold capillary density (NCD) has been linked to a higher risk of subclinical lung involvement (24). In a cohort of 58 patients with JDM, those with low NCD (<6 capillaries/mm) had lower forced vital capacity, total lung capacity and diffusing capacity for carbon monoxide values. Furthermore, signs of airway disease on high-resolution computed tomography were also more prevalent in the group with low NCD (24).

Anti-NXP-2 has been associated with gastrointestinal ulceration while anti-MDA-5 has been linked to skin ulceration (18, 23, 25). A study of a cohort of 285 JDM patients, which included 21 patients positive for anti-MDA-5, showed that these antibodies were associated with skin and oral ulceration (23).

In addition, vasculopathic features identified in the muscle and skin biopsies appear to be related to severe extramuscular manifestations, such as calcinosis, skin ulceration, ILD, and gastrointestinal tract involvement (26-28).

It is well known that calcinosis is one of the most severe complications of JDM. Several factors have been associated with an increased risk of calcinosis development (5, 29-31). A retrospective study involving 490 patients with JDM conducted by Ravelli *et al.* found an association between calcinosis and chronic, prolonged, and active disease (5). Longer disease duration, delay in

**Table 2.** Myositis-specific and myositis-associated antibodies and their implications in juvenile dermatomyositis prognosis.

Antibodies	Implications	References
Anti-synthetase (anti-Jo-1, anti-PL-12, anti-PL-7, anti-OJ, among others)	Higher risk of ILD Increased risk of mortality	(17-19) (4)
Anti-TIF-1- $\gamma$	Increased risk of lipodystrophy Higher risk of skin ulceration Chronic disease with prominent skin involvement	(32) (32) (18)
Anti-Mi-2	Increased muscle weakness and dysphagia Better prognosis (good response to conventional treatment)	(17)
Anti-MDA-5	Rapidly progressive ILD Increased risk of skin ulceration Long-term treatment despite the presence of less severe changes in muscle biopsy Milder muscle involvement	(18, 23) (18, 23) (21) (17, 23)
Anti-NXP-2	Severe muscle involvement Increased risk of calcinosis Increased risk of gastrointestinal ulceration	(17, 18) (17, 18, 30) (16, 18)
Anti-HMGCR	Severe and refractory muscle disease	(17)
Anti-SRP	Severe and refractory muscle disease	(17, 18)
Anti-Ro-52	Severe, chronic, and refractory disease Increased risk of ILD	(19) (19)

ILD, interstitial lung disease; HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase; MDA-5, melanoma differentiation-associated gene 5; NXP-2, nuclear matrix protein 2; SRP, signal recognition particle; TIF-1- $\gamma$ , transcription intermediary factor-1- $\gamma$ .

diagnosis, and longer duration of elevated muscle enzymes were associated with calcinosis in a study conducted by Fisler *et al.* (31). Younger age at onset and anti-NXP-2 antibodies were associated with a higher risk of calcinosis in a cohort of 285 JDM patients aged less than 16 years (30). Additionally, prolonged disease duration, younger age at diagnosis, skin lesions (specifically Gottron papules), and periungual capillary changes were associated with calcinosis in a cohort of 49 patients with JDM, 37 of them diagnosed with JDM (29). Lipodystrophy represents another severe complication and the presence of anti-TIF-1- $\gamma$  antibodies seems to increase this risk (32). Moreover, in Ravelli *et al.*'s study Latin Americans had a higher susceptibility to developing both calcinosis and lipodystrophy in comparison to Europeans (5).

### Predictors of functional impairment

In terms of functional outcomes, some factors have emerged as possible predictors of heightened functional impairment, including delayed diagnosis, inappropriate treatment, female gender, and chronic disease course (5, 31, 33). A retrospective study conducted by Bowyer *et al.* on 47 children with JDM found that patients treated late in the course of the disease and with low doses of corticosteroids were more likely to be functionally limited (33). Patients with chronic disease courses compared to those with monocyclic courses had more functional impairment (5, 34). Furthermore, female gender was identified as a predictor of functional impairment in two previous studies (5, 34).

### Conclusions

In conclusion, certain clinical manifestations and immunological features appear to worsen the prognosis of children with JDM. Some of these include the presence of a chronic disease course, delayed diagnosis, occurrence of calcinosis and lipodystrophy, presence of antisynthetase antibodies, nailfold capillary abnormalities, and vasculopathic features identified in biopsies. Acknowledging these risk factors is essential for all pediatric rheumatologists, as it allows the prompt identification of patients at risk of poorer outcomes. Such patients should receive closer follow-up and tailored, aggressive therapeutic interventions in order to reduce their morbimortality. Thus, while anti-Mi-2 patients are likely to be best managed by standard conventional therapies, those with anti-NXP-2, anti-TIF-1- $\gamma$ , anti-SRP, and anti-HMGCR may benefit from an alternative, more aggressive treatment approach. Patients with anti-MDA-5 and antisynthetase antibodies should be carefully monitored for the development of interstitial lung disease. Further investigation is imperative, not only to identify additional predictors of worse outcomes but also to identify more targeted and efficacious treatment strategies tailored to these patients.

### References

- Huber AM. Juvenile idiopathic inflammatory myopathies. *Pediatr Clin North Am* 2018; 65: 739-56.
- Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. *Br J Rheumatol* 1995; 34: 732-6.
- Huber A, Feldman BM. Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going? *Curr Rheumatol Rep* 2005; 7: 441-6.
- Huber AM, Mamyrova G, Lachenbruch PA, Lee JA, Katz JD, Targoff IN, et al. Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies. *Arthritis Care Res* 2014; 66: 732-40.
- Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. *Arthritis Care Res* 2010; 62: 63-72.
- Sanner H, Sjaastad I, Flato B. Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool. *Rheumatology* 2014; 53: 1578-85.
- Kendall FP ME, Provance PG. *Muscles: testing and function*. 4th edition. Third edition ed: Baltimore: Williams & Wilkins; 1993.
- Lovell DJ, Lindsley CB, Rennebohm RM, Ballinger SH, Bowyer SL, Giannini EH, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group. *Arthritis Rheum* 1999; 42: 2213-9.
- Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. *Rheumatology* 2004; 43: 49-54.
- Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. *Arthritis Rheum* 2003; 49: 7-15.
- Stringer E, Singh-Grewal D, Feldman BM. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. *Arthritis Rheum* 2008; 58: 3585-92.
- Spencer-Green G, Schlesinger M, Bove KE, Levinson JE, Schaller JG, Hanson V, et al. Nailfold capillary abnormalities in childhood rheumatic diseases. *J Pediatr* 1983; 102: 341-6.
- Smith RL, Sundberg J, Shamiyah E, Dyer A, Pachman LM. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. *J Rheumatol* 2004; 31: 1644-9.
- Christen-Zaech S, Seshadri R, Sundberg J, Paller AS, Pachman LM. Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. *Arthritis Rheum* 2008; 58: 571-6.
- Schmelting H, Stephens S, Goia C, Manlhiot C, Schneider R, Luthra S, et al. Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis. *Rheumatology* 2011; 50: 885-93.
- Pachman LM, Nolan BE, DeRanieri D, Khojah AM. Juvenile dermatomyositis: new clues to diagnosis and therapy. *Curr Treatm Opt Rheumatol* 2021; 7: 39-62.
- Tansley SL, Simou S, Shaddick G, Betteridge ZE, Almeida B, Gunawardena H, et al. Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort. *J Autoimmun* 2017; 84: 55-64.



18. Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. *Medicine* 2013; 92: 223-43.
19. Sabbagh S, Pinal-Fernandez I, Kishi T, Targoff IN, Miller FW, Rider LG, et al. Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. *Ann Rheum Dis* 2019; 78: 988-95.
20. Kishi T, Warren-Hicks W, Bayat N, Targoff IN, Huber AM, Ward MM, et al. Corticosteroid discontinuation, complete clinical response and remission in juvenile dermatomyositis. *Rheumatology* 2021; 60: 2134-45.
21. Deakin CT, Yasin SA, Simou S, Arnold KA, Tansley SL, Betteridge ZE, et al. Muscle biopsy findings in combination with myositis-specific autoantibodies aid prediction of outcomes in juvenile dermatomyositis. *Arthritis Rheumatol* 2016; 68: 2806-16.
22. Ladd PE, Emery KH, Salisbury SR, Laor T, Lovell DJ, Bove KE. Juvenile dermatomyositis: correlation of MRI at presentation with clinical outcome. *AJR Am J Roentgenol* 2011; 197: W153-8.
23. Tansley SL, Betteridge ZE, Gunawardena H, Jacques TS, Owens CM, Pilkington C, et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. *Arthritis Res Ther* 2014; 16: R138.
24. Barth Z, Schwartz T, Flato B, Aalokken TM, Koller A, Lund MB, et al. Association between nailfold capillary density and pulmonary and cardiac involvement in medium to longstanding juvenile dermatomyositis. *Arthritis Care Res* 2019; 71: 492-7.
25. Xu Y, Ma X, Zhou Z, Li J, Hou J, Zhu J, et al. Gastrointestinal perforation in anti-NXP2 antibody-associated juvenile dermatomyositis: case reports and a review of the literature. *Pediatr Rheumatol Online J* 2021; 19: 2.
26. Wakiguchi H, Takei S, Imanaka H, Hiraki T, Higashi M, Yamatou T, et al. Severe gluteal skin ulcers in an infant with juvenile dermatomyositis. *Eur J Dermatol* 2016; 26: 192-3.
27. Papadopoulou C, McCann LJ. The vasculopathy of juvenile dermatomyositis. *Front Pediatr* 2018; 6: 284.
28. Chung MP, Richardson C, Kirakossian D, Orandi AB, Saketkoo LA, Rider LG, et al. Calcinosis biomarkers in adult and juvenile dermatomyositis. *Autoimmun Rev* 2020; 19: 102533.
29. Tsaltskan V, Aldous A, Serafi S, Yakovleva A, Sami H, Mamyrova G, et al. Long-term outcomes in juvenile myositis patients. *Semin Arthritis Rheum* 2020; 50: 149-55.
30. Tansley SL, Betteridge ZE, Shaddick G, Gunawardena H, Arnold K, Wedderburn LR, et al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. *Rheumatology* 2014; 53: 2204-8.
31. Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. *J Am Acad Dermatol* 2002; 47: 505-11.
32. Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. *Medicine* 2008; 87: 70-86.
33. Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. *J Pediatr* 1983; 103: 882-8.
34. Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. *Arthritis Rheum* 2000; 43: 541-9.

Contributions: all the authors made a substantial intellectual contribution, read and approved the final version of the manuscript, and agreed to be accountable for all aspects of the work.

Conflict of interest: the authors declare no potential conflict of interest.

Ethics approval and consent to participate: not applicable.

Informed consent: not applicable.

Availability of data and materials: data and materials are available from the corresponding author upon request.

Funding: none.

Received: 27 August 2023.

Accepted: 19 June 2024.

Early access: 11 November 2024.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

©Copyright: the Author(s), 2024

Licensee PAGEPress, Italy

*Reumatismo* 2025; 77:1640

doi:10.4081/reumatismo.2024.1640

*Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.*